Niño-Vega Gustavo A, Ortiz-Ramírez Jorge A, López-Romero Everardo
Departamento de Biología, División de Ciencias Naturales y Exactas, Campus Guanajuato, Universidad de Guanajuato, Noria Alta s/n, col. Noria Alta, Guanajuato C.P. 36050, Mexico.
Antibiotics (Basel). 2025 Apr 15;14(4):404. doi: 10.3390/antibiotics14040404.
The increase in multidrug-resistant organisms worldwide is a major public health threat driven by antibiotic overuse, horizontal gene transfer (HGT), environmental drivers, and deficient infection control in hospitals. In this article, we discuss these factors and summarize the new drugs and treatment strategies suggested to combat the increasing challenges of multidrug-resistant (MDR) bacteria. New treatments recently developed involve targeting key processes involved in bacterial growth, such as riboswitches and proteolysis, and combination therapies to improve efficacy and minimize adverse effects. It also tackles the challenges of the Gram-negative bacterial outer membrane, stressing that novel strategies are needed to evade permeability barriers, efflux pumps, and resistance mechanisms. Other approaches, including phage therapy, AMPs, and AI in drug discovery, are also discussed as potential alternatives. Finally, this review points out the urgency for continued research and development (R&D), industry-academic partnerships, and financial engines to ensure that MDR microbes do not exceed the value of antibacterial therapies.
全球范围内多重耐药菌的增加是一个重大的公共卫生威胁,这是由抗生素过度使用、水平基因转移(HGT)、环境因素以及医院感染控制不足所驱动的。在本文中,我们讨论了这些因素,并总结了为应对多重耐药(MDR)细菌日益增加的挑战而建议的新药和治疗策略。最近开发的新治疗方法包括针对细菌生长所涉及的关键过程,如核糖开关和蛋白水解,以及联合疗法以提高疗效并将不良反应降至最低。它还应对革兰氏阴性菌外膜的挑战,强调需要新的策略来规避通透性屏障、外排泵和耐药机制。还讨论了其他方法,包括噬菌体疗法、抗菌肽以及药物发现中的人工智能,作为潜在的替代方案。最后,本综述指出了持续研发(R&D)、产学研合作以及资金支持的紧迫性,以确保多重耐药微生物不会超过抗菌治疗的价值。